HEIGHTMAXXING 101
Made by
Godveil Heir and
Synapse
TABLE OF CONTENTS
INTRODUCTION
Growth prediction, Tanner stages and Bone age.
This is a CDC chart published in the 2000s based on United States population data. The chart serves as a reference to check if the growth of a child or teenager is on track. By comparing measurements over time, shifts in percentiles might indicate potential health issues. This system helps keep track of an individual’s growth simply by looking at their age and comparing it to the average height percentile for that age group.
Tanner stages are unreliable and bone age aligns with real age for most people
It is very important to understand this since many people still rely on weak or misleading indicators such as facial hair, pubic hair, or other visible signs to assume that growth has stopped. Puberty and skeletal maturation are related but not perfectly synchronized processes. Hormonal changes and secondary sexual characteristics develop at different rates and are strongly influenced by genetics and ethnicity.
For example, a person might appear to be in mid puberty, around Tanner stage three or four, but still have open and responsive growth plates. This shows that external puberty signs are not a reliable way to determine maturity or predict how much growth remains. Even trained physicians have only around 53 to 59 percent accuracy when estimating Tanner stages, with particularly poor accuracy at stage three. This means that up to 40 percent of classifications can be incorrect.
The genetic and ethnic diversity of modern populations in the United States and Europe makes Tanner staging even less reliable. Some people develop facial and pubic hair very early but still have open growth plates, while others may show these signs later when their plates are already closed. This wide variation means that external features give little real information about skeletal maturity.
The best and most objective way to assess growth potential is through bone age evaluation using imaging, preferably with a wrist or knee X ray. Bone age directly shows the condition of the growth plates and gives a more accurate picture of how far along someone is in their biological development. For most individuals, bone age is within about one year of their real age. This means that 95 percent of people have a bone age that closely matches their chronological age. In a typical classroom, you will notice that most students look close to their actual ages, with only a few appearing noticeably older or younger. Those few usually have bone age that is slightly ahead or behind their real age. This pattern shows how closely bone age reflects true physical development in most people.
TLDR: Tanner stages are unreliable because genetics and ethnicity affect how puberty appears physically, while skeletal growth follows its own timeline. A knee X ray remains the most accurate way to determine true bone age and ongoing growth potential.
HGH and AIs (Biology, Protocols, Studies)
Aminoacids chain of HGH Chemical structure of HGH
HGH definition = Now first of all we have to understand what is HGH and the pathways of how it's secreted, but endogenously and exogenously, Human growth hormone is a 191 aminoacids residue chain, It is synthesized by the somatotroph cells in the pituitary gland and acts as a hormone to stimulate growth, cell reproduction, and protein and lipid metabolism.
Endogenous Pathway Secretion
Human growth hormone is as mentioned before endogenously secreted through the next pathway, neurons produce somatocritin (Growth Hormone, Releasing Hormone), GHRH then is released from neurosecretory terminals in the median eminence into the portal venous system, and then following the blood flow it reaches the pituitary gland binding to the GHRH receptors on the somatroph cells, this activates then what is known as the cAMP pathway, which activates the GH gene transcription and triggers the release of stored GH into the bloodstream.
At the same time this occurs then gh regulators such as Somatostatin, are secreted in the periventricular nucleus and a bit in the arcuate nucleus of the hypothalamus. This creates the pulsatile way we all know of how HGH is secreted, pulses usually occurs when somatostatin decreases, allowing its effect domain temporarily. This mechanism is characterized by a self negative feedback meaning GH itself and its main downstream mediator IGF-1 (insulin like growth factor 1), (which is produced by the liver as a response to the presence of gh down the bloodstream), are what keeps this mechanism regulated and in baseline, so this mechanism is self regulated by its own secretion pathway.
image used for depicting the pathway
Another important hormone that highly impacts gh is ghrelin, ghrelin is secreted mainly in the stomach (but also in the hypothalamus), ghrelin acts as a potent gh secretagogue, it's mechanism stimulates GH release both directly (at the pituitary gland) and indirectly by promoting GHRH release while suppressing somatostatin.
How does this affect height?
Well, if it is not kinda obvious hgh directly increases height in children and adolescents by promoting what is commonly known as "longitudinal bone growth" at the epiphyseal plates (also known as growth plates) of long bones (in this case ur legs). GH binds to receptors on chondrocytes (which are the cartilage cells) in the growth plate. Hgh will also induce the localized production of IGF-1 in the growth plate whic will effectively enhance cellular, tissue, and chondrocyte proliferation and hypertrophy, and eventually the ossification of the new cartilage tissue formed, this process lasts all your childhood and adolescence till 16-18, (yes ik some men will grow till 21 but it is rare), this stop at around this age because of estrogen drive epiphyseal fusion occurs which occurs in late adolescence (around 16-18 and in rare cases 21).
At what age does pinning HGH stop making a difference?
The best most optimal time period for effectively increasing height and use of HGH is during early childhood or pre-puberty, when growth plates are open and super responsive. Starting later reduces the efficacy of these compounds, as the window for maximal height gain narrows with age. At 15 the responsiveness is very limited and starts to decline very fast, at 14-13 there is still a lot of growth window as proven by the next studies, In a study of 123 children with ISS treated with recombinant human GH at 0.32 mg/kg/week, treatment started between around the of ages 4.7 and 16 years (men around 12 years), it in fact included 13-14 year olds teens. Subgroups included those with delayed puberty (which is males without testicular development by age 14 and females by age 13), who often started later. Overall, 88 children reached adult height with a gain of 1.90 SDS (about 9.5 cm for males and 8.6 cm for females compared to untreated controls)
key findings of multiple studies demonstrate effectively that starting the use of recombinant HGH in children under 8 years old (girls) or 9 years old (boys) leads to a way greater adult height improvements, often 7-11 cm more than other controls or later starters.
quoting this PuMmed study performed about the effects of hgh as a treatment on ISSS (idiopathic short stature syndrome) https://pmc.ncbi.nlm.nih.gov/articles/PMC4114101/
"Eighty eight of our children (68 males and 20 females) attained an adult height or near adult height of -0.71 SDS (0.74 SD) (95% CI, -0.87 to -0.55) with a benefit over untreated controls of 9.5 cm (7.4 to 11.6 cm) for males and 8.6 cm (6.7 to 10.5 cm) for females."
"Growth hormone treatment significantly increases the adult height, but the benefit obtained with doses of less than 0.3 mg/kg/week is modest, usually less than 4 cm. The benefit obtained seems dose dependent and a benefit of 7, 7.5, and 8 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week."
Now, we do have to note that the studies were performed on kids with ISSS. But theory still checks.
How to properly enhance performance for maximum growth?
For this purpose, an aromatase inhibitor will be used, an AI works by inhibiting the aromatase, aromatase is an enzyme in the cytochrome P450 family found in types of soft and fatty and overall just tissues such as adipose tissue, muscle, skin, brain, and men the testes and growth plates of bones. Its main job is to convert androgens (test, dht etc) through a process known as aromatization to estrogens (estradiol, estrone, etc).
Fun fact cause my balls said so: this process is called demethylation which happens by removing a methyl from the selected androgen molecule and forming a phenolic A ring, converting effectively into a type of estrogens
Follow the correct dosing formula:
Z x weight(KGS) / 7 x 3 = daily gh iu dose
Z = any number between 0.24-0.47
From a safety standpoint it's best to start at 6IUs and work your way up as tolerated to the suggested dosage by the formula
AI = letrozole 2.5 mg once daily or Anastrazole 1mg
References for AI usage and dosage = https://academic.oup.com/jcem/article-abstract/90/12/6396/2837151?redirectedFro
Common heightmaxxing copes evisceration
Leg Lengthening 101
Made by
Godveil Heir and
Synapse TABLE OF CONTENTS
Glossary
Introduction
Growth Chart Prediction, Tanner stage and Bone age
HGH and AIs (Biology, Protocols, Studies)
Myth Debunking
Leg Lengthening (Basics, Devices, Phases, Risks)
Recovery and Enhancement Stacks
Proportions and Biomechanics
References and Resources
Introduction
Growth Chart Prediction, Tanner stage and Bone age
HGH and AIs (Biology, Protocols, Studies)
Myth Debunking
Leg Lengthening (Basics, Devices, Phases, Risks)
Recovery and Enhancement Stacks
Proportions and Biomechanics
References and Resources
Aromatase Inhibitor (AI): Drug that blocks the enzyme converting testosterone to estrogen.
Used to delay growth-plate closure.
Bone Age: X-ray assessment of skeletal maturity (how “old” your bones are vs. chronological age).
Consolidation Phase: Period after lengthening where new bone hardens and strengthens (usually 2–4 months).
Distraction Osteogenesis: Process of slowly pulling cut bone apart so new bone forms in the gap.
Epiphyseal (Growth) Plates: Cartilage areas at the ends of long bones where lengthening occurs; they fuse (close) under estrogen influence, ending natural height growth.
Precice, STRYDE, Fitbone etc.: Telescopic rod implanted inside the bone; lengthened by magnetic remote. Preferred for cosmetics and lower infection risk.
GHRH / Somatostatin / Ghrelin: Key hormones regulating natural HGH pulses.
HGH (Human Growth Hormone / rhGH): 191-amino-acid hormone that drives bone, muscle, and tissue growth. Synthetic version used for height.
IGF-1: Main downstream mediator of HGH; produced mostly in the liver; directly stimulates cartilage growth in growth plates.
ISS (Idiopathic Short Stature): Short stature with no identifiable medical cause.
Latency Phase: 5–7 days after bone is cut before lengthening begins (allows initial healing).
SDS (Standard Deviation Score): How many standard deviations your height is from the average for your age/sex.
Staged Lengthening: One bone segment (or pair of limbs) at a time, with 6–12+ months healing between rounds.
Trenbolone (“Tren”): A potent 19nor anabolic steroid for muscle preservation (very potent, but also harsh side-effect profile).
Used to delay growth-plate closure.
Bone Age: X-ray assessment of skeletal maturity (how “old” your bones are vs. chronological age).
Consolidation Phase: Period after lengthening where new bone hardens and strengthens (usually 2–4 months).
Distraction Osteogenesis: Process of slowly pulling cut bone apart so new bone forms in the gap.
Epiphyseal (Growth) Plates: Cartilage areas at the ends of long bones where lengthening occurs; they fuse (close) under estrogen influence, ending natural height growth.
Precice, STRYDE, Fitbone etc.: Telescopic rod implanted inside the bone; lengthened by magnetic remote. Preferred for cosmetics and lower infection risk.
GHRH / Somatostatin / Ghrelin: Key hormones regulating natural HGH pulses.
HGH (Human Growth Hormone / rhGH): 191-amino-acid hormone that drives bone, muscle, and tissue growth. Synthetic version used for height.
IGF-1: Main downstream mediator of HGH; produced mostly in the liver; directly stimulates cartilage growth in growth plates.
ISS (Idiopathic Short Stature): Short stature with no identifiable medical cause.
Latency Phase: 5–7 days after bone is cut before lengthening begins (allows initial healing).
SDS (Standard Deviation Score): How many standard deviations your height is from the average for your age/sex.
Staged Lengthening: One bone segment (or pair of limbs) at a time, with 6–12+ months healing between rounds.
Trenbolone (“Tren”): A potent 19nor anabolic steroid for muscle preservation (very potent, but also harsh side-effect profile).
INTRODUCTION
.This guide outlines all established height optimization methods, from HGH and aromatase inhibitors to limb lengthening surgery, while clarifying common myths with straightforward evidence.
It provides precise protocols for HGH and AI use, including dosing and oversight.
The leg lengthening section answers key questions on surgeons, costs, risks, and preparation upfront. Once fundamentals are covered, LL forums offer surgeon picks and planning details. Approach systematically for best results.
It provides precise protocols for HGH and AI use, including dosing and oversight.
The leg lengthening section answers key questions on surgeons, costs, risks, and preparation upfront. Once fundamentals are covered, LL forums offer surgeon picks and planning details. Approach systematically for best results.
Growth prediction, Tanner stages and Bone age.
This is a CDC chart published in the 2000s based on United States population data. The chart serves as a reference to check if the growth of a child or teenager is on track. By comparing measurements over time, shifts in percentiles might indicate potential health issues. This system helps keep track of an individual’s growth simply by looking at their age and comparing it to the average height percentile for that age group.
Tanner stages are unreliable and bone age aligns with real age for most people
It is very important to understand this since many people still rely on weak or misleading indicators such as facial hair, pubic hair, or other visible signs to assume that growth has stopped. Puberty and skeletal maturation are related but not perfectly synchronized processes. Hormonal changes and secondary sexual characteristics develop at different rates and are strongly influenced by genetics and ethnicity.
For example, a person might appear to be in mid puberty, around Tanner stage three or four, but still have open and responsive growth plates. This shows that external puberty signs are not a reliable way to determine maturity or predict how much growth remains. Even trained physicians have only around 53 to 59 percent accuracy when estimating Tanner stages, with particularly poor accuracy at stage three. This means that up to 40 percent of classifications can be incorrect.
The genetic and ethnic diversity of modern populations in the United States and Europe makes Tanner staging even less reliable. Some people develop facial and pubic hair very early but still have open growth plates, while others may show these signs later when their plates are already closed. This wide variation means that external features give little real information about skeletal maturity.
The best and most objective way to assess growth potential is through bone age evaluation using imaging, preferably with a wrist or knee X ray. Bone age directly shows the condition of the growth plates and gives a more accurate picture of how far along someone is in their biological development. For most individuals, bone age is within about one year of their real age. This means that 95 percent of people have a bone age that closely matches their chronological age. In a typical classroom, you will notice that most students look close to their actual ages, with only a few appearing noticeably older or younger. Those few usually have bone age that is slightly ahead or behind their real age. This pattern shows how closely bone age reflects true physical development in most people.
TLDR: Tanner stages are unreliable because genetics and ethnicity affect how puberty appears physically, while skeletal growth follows its own timeline. A knee X ray remains the most accurate way to determine true bone age and ongoing growth potential.
HGH and AIs (Biology, Protocols, Studies)
Aminoacids chain of HGH Chemical structure of HGH
HGH definition = Now first of all we have to understand what is HGH and the pathways of how it's secreted, but endogenously and exogenously, Human growth hormone is a 191 aminoacids residue chain, It is synthesized by the somatotroph cells in the pituitary gland and acts as a hormone to stimulate growth, cell reproduction, and protein and lipid metabolism.
Endogenous Pathway Secretion
Human growth hormone is as mentioned before endogenously secreted through the next pathway, neurons produce somatocritin (Growth Hormone, Releasing Hormone), GHRH then is released from neurosecretory terminals in the median eminence into the portal venous system, and then following the blood flow it reaches the pituitary gland binding to the GHRH receptors on the somatroph cells, this activates then what is known as the cAMP pathway, which activates the GH gene transcription and triggers the release of stored GH into the bloodstream.
At the same time this occurs then gh regulators such as Somatostatin, are secreted in the periventricular nucleus and a bit in the arcuate nucleus of the hypothalamus. This creates the pulsatile way we all know of how HGH is secreted, pulses usually occurs when somatostatin decreases, allowing its effect domain temporarily. This mechanism is characterized by a self negative feedback meaning GH itself and its main downstream mediator IGF-1 (insulin like growth factor 1), (which is produced by the liver as a response to the presence of gh down the bloodstream), are what keeps this mechanism regulated and in baseline, so this mechanism is self regulated by its own secretion pathway.
image used for depicting the pathway
Another important hormone that highly impacts gh is ghrelin, ghrelin is secreted mainly in the stomach (but also in the hypothalamus), ghrelin acts as a potent gh secretagogue, it's mechanism stimulates GH release both directly (at the pituitary gland) and indirectly by promoting GHRH release while suppressing somatostatin.
How does this affect height?
Well, if it is not kinda obvious hgh directly increases height in children and adolescents by promoting what is commonly known as "longitudinal bone growth" at the epiphyseal plates (also known as growth plates) of long bones (in this case ur legs). GH binds to receptors on chondrocytes (which are the cartilage cells) in the growth plate. Hgh will also induce the localized production of IGF-1 in the growth plate whic will effectively enhance cellular, tissue, and chondrocyte proliferation and hypertrophy, and eventually the ossification of the new cartilage tissue formed, this process lasts all your childhood and adolescence till 16-18, (yes ik some men will grow till 21 but it is rare), this stop at around this age because of estrogen drive epiphyseal fusion occurs which occurs in late adolescence (around 16-18 and in rare cases 21).
At what age does pinning HGH stop making a difference?
The best most optimal time period for effectively increasing height and use of HGH is during early childhood or pre-puberty, when growth plates are open and super responsive. Starting later reduces the efficacy of these compounds, as the window for maximal height gain narrows with age. At 15 the responsiveness is very limited and starts to decline very fast, at 14-13 there is still a lot of growth window as proven by the next studies, In a study of 123 children with ISS treated with recombinant human GH at 0.32 mg/kg/week, treatment started between around the of ages 4.7 and 16 years (men around 12 years), it in fact included 13-14 year olds teens. Subgroups included those with delayed puberty (which is males without testicular development by age 14 and females by age 13), who often started later. Overall, 88 children reached adult height with a gain of 1.90 SDS (about 9.5 cm for males and 8.6 cm for females compared to untreated controls)
key findings of multiple studies demonstrate effectively that starting the use of recombinant HGH in children under 8 years old (girls) or 9 years old (boys) leads to a way greater adult height improvements, often 7-11 cm more than other controls or later starters.
quoting this PuMmed study performed about the effects of hgh as a treatment on ISSS (idiopathic short stature syndrome) https://pmc.ncbi.nlm.nih.gov/articles/PMC4114101/
"Eighty eight of our children (68 males and 20 females) attained an adult height or near adult height of -0.71 SDS (0.74 SD) (95% CI, -0.87 to -0.55) with a benefit over untreated controls of 9.5 cm (7.4 to 11.6 cm) for males and 8.6 cm (6.7 to 10.5 cm) for females."
"Growth hormone treatment significantly increases the adult height, but the benefit obtained with doses of less than 0.3 mg/kg/week is modest, usually less than 4 cm. The benefit obtained seems dose dependent and a benefit of 7, 7.5, and 8 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week."
Now, we do have to note that the studies were performed on kids with ISSS. But theory still checks.
How to properly enhance performance for maximum growth?
For this purpose, an aromatase inhibitor will be used, an AI works by inhibiting the aromatase, aromatase is an enzyme in the cytochrome P450 family found in types of soft and fatty and overall just tissues such as adipose tissue, muscle, skin, brain, and men the testes and growth plates of bones. Its main job is to convert androgens (test, dht etc) through a process known as aromatization to estrogens (estradiol, estrone, etc).
Fun fact cause my balls said so: this process is called demethylation which happens by removing a methyl from the selected androgen molecule and forming a phenolic A ring, converting effectively into a type of estrogens
Follow the correct dosing formula:
Z x weight(KGS) / 7 x 3 = daily gh iu dose
Z = any number between 0.24-0.47
From a safety standpoint it's best to start at 6IUs and work your way up as tolerated to the suggested dosage by the formula
AI = letrozole 2.5 mg once daily or Anastrazole 1mg
References for AI usage and dosage = https://academic.oup.com/jcem/article-abstract/90/12/6396/2837151?redirectedFro
Common heightmaxxing copes evisceration
First of all, if you unironically believe any of this, apply for state benefits for mental retardation. And that you can surpass established genetic and biology limits using “natural” methods, the whole idea is flawed.
GHRPs (Growth Hormone-Releasing Peptides)
MK677
Masai Jumps
Raw honey and Milk
Diet
Sleep
Spine decompression (banded sleep)
Sprinting
Subliminals
Sugar Diet
GHRPs (Growth Hormone-Releasing Peptides)
Claim: Pinning GHRPs (GHRP-6, Hexarelin, CJC) supposedly spikes HGH levels, leading to height growth even in adults by stimulating bone lengthening, very common question/claim asked on looksmax. org btw "Muh saaar will CJC DAC and MK677 make 6'7 feet tall nnn shieeeetttt" .
Debunk: Well guess what? fucking not, won't do shit, let me further elaborate, it is a total pseudoscience for adults. GHRPs do boost HGH secretion, but way less than real good old hgh, here is were is ask you, why get something that achieves less while being more expensive?, and BTW this could only aids height in kids with deficiencies like idiopathic short stature (ISS), where gains are very modest, HGH has always been the way to go treat ISS precisely cause it tera mogs the performance of any GHRP to the slums of islamabad. In adults it wont do shit cause growth plates are closed as explained by the HGH and AIs section, so the tissue cant replicate and elongate and then ossify, so total myth and anyways, again, more expensive than HGH and you will achieve just a fraction of what real HGH can do.
Debunk: Well guess what? fucking not, won't do shit, let me further elaborate, it is a total pseudoscience for adults. GHRPs do boost HGH secretion, but way less than real good old hgh, here is were is ask you, why get something that achieves less while being more expensive?, and BTW this could only aids height in kids with deficiencies like idiopathic short stature (ISS), where gains are very modest, HGH has always been the way to go treat ISS precisely cause it tera mogs the performance of any GHRP to the slums of islamabad. In adults it wont do shit cause growth plates are closed as explained by the HGH and AIs section, so the tissue cant replicate and elongate and then ossify, so total myth and anyways, again, more expensive than HGH and you will achieve just a fraction of what real HGH can do.
MK677
Claim: same as CJC and Hexa
Debunk: MK677 is an oral secretagogue that mimics ghrelin studies shot that IGF-1 (50–80% in studies), however just as cjc and hexa it does the job poorly, severely spikes cortisol and hunger while also spiking prolactin and for height growth (chondrocyte activity and proliferation and finally ossification) benefits from sustained GH/IGF-1 signaling. Peptides give big pulses followed by deep troughs and a feedback shutdown making a very poor job and keeping steady HGH levels needed for height growth, exogenous HGH gives very steady localized and circulating levels, which is why it’s superior in every clinical growth study performed and the best tool for treating kids with ISS, and by the price hgh mogs hard.
Debunk: MK677 is an oral secretagogue that mimics ghrelin studies shot that IGF-1 (50–80% in studies), however just as cjc and hexa it does the job poorly, severely spikes cortisol and hunger while also spiking prolactin and for height growth (chondrocyte activity and proliferation and finally ossification) benefits from sustained GH/IGF-1 signaling. Peptides give big pulses followed by deep troughs and a feedback shutdown making a very poor job and keeping steady HGH levels needed for height growth, exogenous HGH gives very steady localized and circulating levels, which is why it’s superior in every clinical growth study performed and the best tool for treating kids with ISS, and by the price hgh mogs hard.
Masai Jumps
Claim: The Maasai tribes' high jumps create "microfractures" in leg bones, triggering "Wolff's Law" to make bones longer and increase height.
Debunk: Retarded baby shitley and oscar patel pseudoscience and failing to understand what wolfs law works, just retarded af, plus it doesn't create new cartilage formation at all so as now new tissue is being created by the growth plates none can ossify and even if it worked it would not create vertical height.
Debunk: Retarded baby shitley and oscar patel pseudoscience and failing to understand what wolfs law works, just retarded af, plus it doesn't create new cartilage formation at all so as now new tissue is being created by the growth plates none can ossify and even if it worked it would not create vertical height.
Raw honey and Milk
Claim: The “natural hormones” and nutrients contained by raw milk plus honey's nutrients create a super growth inducing cocktail that boosts height, especially if consumed daily. Super common claim by low iq retards like face negative canthal tilt iq or retards like Bloatis.
Debunk: Correlation, zero causation whatsoever. Milk aids childhood growth via protein/calcium (0.11-0.13 inch/year more in high-milk kids), but only prevents height stunting in undernourished populations, so unless you are form part of this data set this wont apply to you,, no magic height increase will occur if you are not unhealthy, even if you are it won't make any visible difference at all because u can compensate with mild stuff years of conditions like denutrition, and what about honey? Zero evidence for height that could theoretically suggest any causation or even correlation for height increase, it's just contains at most antioxidants/sugar.
Debunk: Correlation, zero causation whatsoever. Milk aids childhood growth via protein/calcium (0.11-0.13 inch/year more in high-milk kids), but only prevents height stunting in undernourished populations, so unless you are form part of this data set this wont apply to you,, no magic height increase will occur if you are not unhealthy, even if you are it won't make any visible difference at all because u can compensate with mild stuff years of conditions like denutrition, and what about honey? Zero evidence for height that could theoretically suggest any causation or even correlation for height increase, it's just contains at most antioxidants/sugar.
Diet
Claim: Specific types of diets like the ones promoted by tik tok retards Jester Patel, Bloatis and Face Low IQ (high-protein, nutrient-dense) can restart growth in adults or super aid growth in teens/kids.
Debunk: Genetics rule as always around 90%; diet optimizes some childhood height potential but doesn't add adult height inches or will make you surpass your parents genetic potential. This is not to promote the intake of slop but we have to understand and comprehend the limitations set by nature, as this cant reverse fused growth plates and can’t “open them” either.
Supplement Formulas
Claim: Some blends like arginine/lysine or "height gummies" boost HGH/IGF-1 for extra growth.
Debunk: Minimal evidence. Amino acids spike HGH short-term (682% in one study), but don't lengthen bones post-puberty and mechanistically are very weak to cause any prolonged spike. Don't fall for the joos propaganda, and also, most of the bioavailability of supplements sucks unless specific mixes which vary from compound to compound, so no, you wont grow till 10'2 by taking this Rajeet.
Debunk: Genetics rule as always around 90%; diet optimizes some childhood height potential but doesn't add adult height inches or will make you surpass your parents genetic potential. This is not to promote the intake of slop but we have to understand and comprehend the limitations set by nature, as this cant reverse fused growth plates and can’t “open them” either.
Supplement Formulas
Claim: Some blends like arginine/lysine or "height gummies" boost HGH/IGF-1 for extra growth.
Debunk: Minimal evidence. Amino acids spike HGH short-term (682% in one study), but don't lengthen bones post-puberty and mechanistically are very weak to cause any prolonged spike. Don't fall for the joos propaganda, and also, most of the bioavailability of supplements sucks unless specific mixes which vary from compound to compound, so no, you wont grow till 10'2 by taking this Rajeet.
Sleep
Claim: Getting 10+ hours of deep sleep (especially "nighttime only") spikes growth hormone (GH) tons of growth hormone release aiding or even creating a super charged environment and can even aid surpass your self genetic limitations.
Debunk: Sleep is crucial for reaching your genetic height potential during childhood and in some parts adolescence, but won't make you surpass your established genetic potential, as this process does not re-code your DNA . GH does indeed get secreted by controlled release in pulses during deep slow-wave sleep (especially early in the night), and chronic sleep deprivation can suppress GH and stunt growth in kids if severe and long term. However, research conducted on very young children ("toddlers to age 3") revealed that an extended nighttime sleep (≥11.5 hours vs. ≤9) is associated with an increased chance of achieving a "tall stature" (above the 75th percentile), with adjusted odds ratios reaching 1.25 in substantial group studies such as the Japan Environment and Children's Study. Overall sleep duration (including naps) showed no significant correlation to make a difference, but rather, adequate nighttime deep sleep is what truly affects GH pulses and matters the most for increased adult height. And for the rest? Nothing, zero evidence that could prove sleep is crucial and insufficient evidence that sleep deprivation directly causes height deficits in well-nourished populations and adolescents fitting in that percentile.Sleep matters for brain function more and is dependent, this is not to promote not sleeping, but to understand the limitations from it and that it won't make you surpass your genetic potential.
Debunk: Sleep is crucial for reaching your genetic height potential during childhood and in some parts adolescence, but won't make you surpass your established genetic potential, as this process does not re-code your DNA . GH does indeed get secreted by controlled release in pulses during deep slow-wave sleep (especially early in the night), and chronic sleep deprivation can suppress GH and stunt growth in kids if severe and long term. However, research conducted on very young children ("toddlers to age 3") revealed that an extended nighttime sleep (≥11.5 hours vs. ≤9) is associated with an increased chance of achieving a "tall stature" (above the 75th percentile), with adjusted odds ratios reaching 1.25 in substantial group studies such as the Japan Environment and Children's Study. Overall sleep duration (including naps) showed no significant correlation to make a difference, but rather, adequate nighttime deep sleep is what truly affects GH pulses and matters the most for increased adult height. And for the rest? Nothing, zero evidence that could prove sleep is crucial and insufficient evidence that sleep deprivation directly causes height deficits in well-nourished populations and adolescents fitting in that percentile.Sleep matters for brain function more and is dependent, this is not to promote not sleeping, but to understand the limitations from it and that it won't make you surpass your genetic potential.
Spine decompression (banded sleep)
Claim: Decompressing the spine via hanging or devices adds permanent height by expanding disc space.
Debunk: Temporary illusion at best. Decompression can restore disc height (1.3mm average per disc), adding 0.25-0.5 inches temporarily, but it reverts under gravity, as when you are standing and walking during the day the earth's gravity will compress it again. No permanent gains can be seen at all from this, just jestermaxxing method, yes Blakespeaks u are wrong and a jester, just stfu.
Debunk: Temporary illusion at best. Decompression can restore disc height (1.3mm average per disc), adding 0.25-0.5 inches temporarily, but it reverts under gravity, as when you are standing and walking during the day the earth's gravity will compress it again. No permanent gains can be seen at all from this, just jestermaxxing method, yes Blakespeaks u are wrong and a jester, just stfu.
Sprinting
Claim Sprinting or HIT can spike high causing more growth and therefore increase height as hgh does surges from sprinting.
Debunk: The acute response which many influencers talk about is real, a single 30-second full speed sprint can spike GH significantly (200–700%+ in young men), but natural physiological body adaptation kills the effect. After 5-6 weeks of sprint training, the GH response to sprints is blunted by (40–55% and even lower), and this spike is so short lived to promote any real hgh and therefore no cartilage tissue growth at the epiphyseal plate and therefore no ossification or elongation. So it is so bad it’s even counterproductive.
Debunk: The acute response which many influencers talk about is real, a single 30-second full speed sprint can spike GH significantly (200–700%+ in young men), but natural physiological body adaptation kills the effect. After 5-6 weeks of sprint training, the GH response to sprints is blunted by (40–55% and even lower), and this spike is so short lived to promote any real hgh and therefore no cartilage tissue growth at the epiphyseal plate and therefore no ossification or elongation. So it is so bad it’s even counterproductive.
Subliminals
just kys if you believe this
Claim: subliminals will have a placebo effect and create similar effects if you believe in them.
Debunk: no scientific evidence, zero, not one molecule, wont even bother wasting my time and wont further elaborate on this.
Claim: subliminals will have a placebo effect and create similar effects if you believe in them.
Debunk: no scientific evidence, zero, not one molecule, wont even bother wasting my time and wont further elaborate on this.
Sugar Diet
Claim: sugar triggers an insulin response so therefore, Insulin + energy = GH/IGF-1 explosion or (what he calls it IGF1 signaling)
Debunk:A high sugar intake/ diet triggers massive insulin release from the body, now the issue with this that it actually suppresses GH secretion (acute drop lasts 2–3 hours post-meal), creating a complete disruption of the natural self regulating HGH axis, especially when chronic high sugar intake is experienced (what he promotes by eating a shit ton of sugar every hour) and also, excess sugar spikes insulin, suppresses GH, promotes fat gain, and risks several metabolic issues/diabetes.And does nothing
As it doesn't have the constant steady levels of pharma HGH which is needed to flow through the bloodstream and then localized to the growth plates tissue.
Debunk:A high sugar intake/ diet triggers massive insulin release from the body, now the issue with this that it actually suppresses GH secretion (acute drop lasts 2–3 hours post-meal), creating a complete disruption of the natural self regulating HGH axis, especially when chronic high sugar intake is experienced (what he promotes by eating a shit ton of sugar every hour) and also, excess sugar spikes insulin, suppresses GH, promotes fat gain, and risks several metabolic issues/diabetes.And does nothing
As it doesn't have the constant steady levels of pharma HGH which is needed to flow through the bloodstream and then localized to the growth plates tissue.
Leg Lengthening 101
The Basics of LL
Types of LL devices
image use to depict how they work
Fully Internal Nails (Precise, STRYDE, Fitbone)
How it works: A telescopic rod inside the bone lengthens with an external remote (magnetic or motorized).
Pros:
No external pins so a lower infection risk.
Better comfort and mobility during distraction.
Easier to hide socially.
Cons:
expensive.
Best for: Those willing to pay for comfort, aesthetics, and lower day-to-day hassle.
LON (Lengthening Over Nail)
LON (Lengthening Over Nail) How it works: External fixator starts the lengthening, but there’s an internal nail from the start. Once length is achieved, frame is removed, nail supports healing.
Pros:
Cheaper than full internal.
Frame removal happens earlier than pure external methods.
Also minimal scarring.
Cons:
Pin site infections are common. This is what raped that delusional Looksmaxxing Channel guy with Sean o’ pry pfp.
"just go to Turkey bro, it's cheaper brutal"
The frame phase is still awkward for walking and sleeping.
Can’t do quadrilaterals with this and will need to use the internal for 2 limbs minimum.
Externals
Not worth consideration, jestermaxxed af. Will rape you with so many scars. Everybody gonna know you did LL & think you’re retarded. You’ll look disgusting. not ideal at all for aesthetics.
NOTE: risk and aesthetically wise your best bet is a system that incorporates fully internal nails, less risky and less hassle.
Risks & Complications
Phases of LL
Max safe & Limitations
Quadrilateral Lengthening
Recovery after surgery
Roids HGH & Peptides for LL Recovery
Proportion & Biomechanics
Leg lengthening is a surgical procedure aimed at increasing the length of the leg bones, the femur (thigh bone) and tibia (shin bone). The surgery begins with an osteotomy, where the bone is carefully cut. A specialized device is then used to slowly pull the bone segments apart over time (distraction osteogenesis), stimulating the body to create new bone in the gap. This gradual advancement process typically allows lengthening of up to about 5 cm (2 inches) per bone in a single round. Larger gains can be achieved through staged procedures.
fig 1 and 2 showing a diagram of distraction osteogenesis
Distraction Osteogenesis Speed
The key component of a successful leg lengthening is the distraction speed which is commonly set at approximately 1 millimeter per day (often divided into four adjustments of 0.25 mm every 6 hours). This rate is considered the most optimal because it allows new bone tissue and the surrounding blood vessels, nerves, muscles, and surrounding skin to adapt and stabilize at a safe pace without compromising their integrity when performing the lengthening process, and also avoiding what is premature bone consolidation. This can allow a safer, more stable augmentation. Distraction faster than 1 mm/day risks poor bone regeneration and also soft tissue damage, while a slower rate would not be ideal either because it may highly lead to premature healing and insufficient lengthening complicating the process, so 1mm a day is the sweet spot.
Age healing factor
This 1 mm/day distraction rate is generally applied to patients from children to young adults up to around 30 years old who have good bone healing capacity, this age group heals around the same. For older patients, especially those of advanced age, distraction is usually done more slowly eg. 0.6mm/ day to accommodate slower bone regeneration and reduce complications so even with less augmentation per day very similar or the same results can usually be achieved with proper planning.
This is how it’s performed
WARNING: THIS VIDEO CONTAINS SENSITIVE IMAGERY AND ITS NSFW, DISCRETION IS ADVISED.
www.youtube.com/watch?feature=shared&t=547&v=NnogB3gi3Rk
Rod removal
It’s not 100% necessary but recommended to avoid future complications, it can be removed after the consolidation phase but usually delayed till full healing. Don’t need to go to the same surgeon who put it in, it’s relatively easy & 1 day procedure. The external device is removed right after lengthening — here I mean the internal device.
fig 1 and 2 showing a diagram of distraction osteogenesis
Distraction Osteogenesis Speed
The key component of a successful leg lengthening is the distraction speed which is commonly set at approximately 1 millimeter per day (often divided into four adjustments of 0.25 mm every 6 hours). This rate is considered the most optimal because it allows new bone tissue and the surrounding blood vessels, nerves, muscles, and surrounding skin to adapt and stabilize at a safe pace without compromising their integrity when performing the lengthening process, and also avoiding what is premature bone consolidation. This can allow a safer, more stable augmentation. Distraction faster than 1 mm/day risks poor bone regeneration and also soft tissue damage, while a slower rate would not be ideal either because it may highly lead to premature healing and insufficient lengthening complicating the process, so 1mm a day is the sweet spot.
Age healing factor
This 1 mm/day distraction rate is generally applied to patients from children to young adults up to around 30 years old who have good bone healing capacity, this age group heals around the same. For older patients, especially those of advanced age, distraction is usually done more slowly eg. 0.6mm/ day to accommodate slower bone regeneration and reduce complications so even with less augmentation per day very similar or the same results can usually be achieved with proper planning.
This is how it’s performed
WARNING: THIS VIDEO CONTAINS SENSITIVE IMAGERY AND ITS NSFW, DISCRETION IS ADVISED.
www.youtube.com/watch?feature=shared&t=547&v=NnogB3gi3Rk
Rod removal
It’s not 100% necessary but recommended to avoid future complications, it can be removed after the consolidation phase but usually delayed till full healing. Don’t need to go to the same surgeon who put it in, it’s relatively easy & 1 day procedure. The external device is removed right after lengthening — here I mean the internal device.
Types of LL devices
image use to depict how they work
Fully Internal Nails (Precise, STRYDE, Fitbone)
How it works: A telescopic rod inside the bone lengthens with an external remote (magnetic or motorized).
Pros:
No external pins so a lower infection risk.
Better comfort and mobility during distraction.
Easier to hide socially.
Cons:
expensive.
Best for: Those willing to pay for comfort, aesthetics, and lower day-to-day hassle.
LON (Lengthening Over Nail)
LON (Lengthening Over Nail) How it works: External fixator starts the lengthening, but there’s an internal nail from the start. Once length is achieved, frame is removed, nail supports healing.
Pros:
Cheaper than full internal.
Frame removal happens earlier than pure external methods.
Also minimal scarring.
Cons:
Pin site infections are common. This is what raped that delusional Looksmaxxing Channel guy with Sean o’ pry pfp.
"just go to Turkey bro, it's cheaper brutal"
The frame phase is still awkward for walking and sleeping.
Can’t do quadrilaterals with this and will need to use the internal for 2 limbs minimum.
Externals
Not worth consideration, jestermaxxed af. Will rape you with so many scars. Everybody gonna know you did LL & think you’re retarded. You’ll look disgusting. not ideal at all for aesthetics.
NOTE: risk and aesthetically wise your best bet is a system that incorporates fully internal nails, less risky and less hassle.
Risks & Complications
With a good clinic and surgeon , most of these are rare and easily prevented)
Fat Embolism (FES) = Fat from bone marrow enters the bloodstream; severe cases can affect lungs.
Likelihood = Microscopic fat enters blood in all cases, but symptomatic FES is = 1% with modern precautions; severe ICU-level cases are -0.06%.
Prevention = Slow and careful reaming, venting the bone, IV albumin,
strict no-nicotine for 3+ months.
If it happens – Usually mild & treated with oxygen; severe cases get ICU care (full recovery likely with early treatment).
Pulmonary Embolism (PE)= Blood clot travels to lungs.
Likelihood = Almost zero now at Paley’s center; past spike (6–7%) was during peak COVID clotting.
Prevention =Daily blood thinners, early walking, extra monitoring for high-risk patients.
If it happens = Treated with anticoagulants until the clot dissolves.
Muscle Contracture = Tight muscles limit joint movement during lengthening.
Likelihood = Common if patient skips stretching; very low if compliant.
Prevention = Aggressive daily stretching & splints; pause lengthening if range drops too much.
If it happens = PT usually restores range; surgery very rarely needed.
Delayed Union / Non-Union = Bone heals slower than expected.
Likelihood = 0% complete non-union in Paley’s stature patients to date.
Prevention = Correct distraction speed, small-incision bone cut, keep vitamin D high.
If it happens = Adjust speed, use bone stimulators, rare bone graft.
Premature Consolidation = Bone heals too quickly before target length is reached.
Likelihood – Rare in adults.
Prevention – Maintain exact distraction speed; check devices often.
If it happens – Re-break bone or adjust device.
Peroneal Nerve Compression = Nerve at knee gets compressed and foot drop risk.
Likelihood = Pain fairly common, actual weakness rare.
Prevention = Preventive decompression in high-risk patients.
If it happens = Immediate decompression (near 100% recovery if early).
Malalignment = Bone drifts out of the correct angle.
Likelihood = Almost zero with proper blocking screws.
Prevention = Correct starting point & nail placement.
If it happens = Corrective surgery.
IT Band Tightness = Tight fascia affects gait.
Likelihood = Common without release; rare with it.
Prevention = IT band release during femur surgery if needed.
If it happens = Fascia loosens naturally during recovery.
Fat Embolism (FES) = Fat from bone marrow enters the bloodstream; severe cases can affect lungs.
Likelihood = Microscopic fat enters blood in all cases, but symptomatic FES is = 1% with modern precautions; severe ICU-level cases are -0.06%.
Prevention = Slow and careful reaming, venting the bone, IV albumin,
strict no-nicotine for 3+ months.
If it happens – Usually mild & treated with oxygen; severe cases get ICU care (full recovery likely with early treatment).
Pulmonary Embolism (PE)= Blood clot travels to lungs.
Likelihood = Almost zero now at Paley’s center; past spike (6–7%) was during peak COVID clotting.
Prevention =Daily blood thinners, early walking, extra monitoring for high-risk patients.
If it happens = Treated with anticoagulants until the clot dissolves.
Muscle Contracture = Tight muscles limit joint movement during lengthening.
Likelihood = Common if patient skips stretching; very low if compliant.
Prevention = Aggressive daily stretching & splints; pause lengthening if range drops too much.
If it happens = PT usually restores range; surgery very rarely needed.
Delayed Union / Non-Union = Bone heals slower than expected.
Likelihood = 0% complete non-union in Paley’s stature patients to date.
Prevention = Correct distraction speed, small-incision bone cut, keep vitamin D high.
If it happens = Adjust speed, use bone stimulators, rare bone graft.
Premature Consolidation = Bone heals too quickly before target length is reached.
Likelihood – Rare in adults.
Prevention – Maintain exact distraction speed; check devices often.
If it happens – Re-break bone or adjust device.
Peroneal Nerve Compression = Nerve at knee gets compressed and foot drop risk.
Likelihood = Pain fairly common, actual weakness rare.
Prevention = Preventive decompression in high-risk patients.
If it happens = Immediate decompression (near 100% recovery if early).
Malalignment = Bone drifts out of the correct angle.
Likelihood = Almost zero with proper blocking screws.
Prevention = Correct starting point & nail placement.
If it happens = Corrective surgery.
IT Band Tightness = Tight fascia affects gait.
Likelihood = Common without release; rare with it.
Prevention = IT band release during femur surgery if needed.
If it happens = Fascia loosens naturally during recovery.
Phases of LL
The treatment process usually involves:
chart depicting the time span
Latency phase = Starts 5–7 days after surgery before lengthening starts. They wait a week after cutting your legs and inserting rod before they start lengthening.
Distraction / lengthening phase = around 80 days. Daily small adjustments of 1 mm per day (for patients < 30+ years old) until the desired length is achieved, followed by monitoring for bone healing and soft tissue adaptation.
Consolidation phase = Around 12 weeks. Bone hardens and strengthens around the new length. Again this is very age and patient dependent.
Full treatment often spans several months, with intensive physical therapy required to maintain flexibility, prevent stiffness, and rebuild muscle strength.
chart depicting the time span
Latency phase = Starts 5–7 days after surgery before lengthening starts. They wait a week after cutting your legs and inserting rod before they start lengthening.
Distraction / lengthening phase = around 80 days. Daily small adjustments of 1 mm per day (for patients < 30+ years old) until the desired length is achieved, followed by monitoring for bone healing and soft tissue adaptation.
Consolidation phase = Around 12 weeks. Bone hardens and strengthens around the new length. Again this is very age and patient dependent.
Full treatment often spans several months, with intensive physical therapy required to maintain flexibility, prevent stiffness, and rebuild muscle strength.
Max safe & Limitations
Everyone wants max height for the pain they’re about to go through. But there are hard limits set by your own anatomy, not just by the bone. You’re not just stretching bone, you’re stretching every single piece of soft tissue that runs alongside it. Nerves are what determine max length the most & no peptide can dramatically speed up their adaptation.
Safe Length Guidelines Femurs: Around 8 cm in one surgery is the accepted safe limit for most people.
Tibias: Around 6 cm in one surgery is the accepted safe limit.
These aren’t arbitrary, they come from decades of data on when complication rates spike sharply.
Why These Limits Exist When you lengthen, every soft tissue structure crossing that bone has to elongate:
Muscles = quadriceps, hamstrings, gastrocnemius, soleus, tibialis anterior, etc.
Tendons = patellar tendon, Achilles tendon.
Fascia = iliotibial band, crural fascia.
Nerves = sciatic, peroneal, tibial nerve.
Blood vessels – femoral artery/vein, popliteal vessels.
These tissues can only adapt so fast before something gives. Go past tissue tolerance, and you risk:
Permanent joint contractures.
Nerve palsy (foot drop, numbness).
Chronic pain and gait issues.
You can’t really get extra length with roids/peptides either. You can make it easier to quickly walk properly, but more length is not highly achievable mainly because of nerves not being sped up dramatically with roids. Now, Does that mean 14 cm, That’s All I Can Get? Good news for you, NO, you can gain 20cm or more, If you’re patient, you can push it up to 20 cm total safely. You just need to respect how long it takes your soft tissue to adapt before going in for round two. The realistic way to hit 20 cm:
First surgery: 8 cm femur + 6 cm tibia = 14 cm Wait 1 year (let your muscles, tendons, fascia, and nerves fully adapt).
Second surgery: Another 6 cm on the tibia tho it will depend on you initial proportions, not everyone can gain 20cm.
Why not double surgery on femur? look up last chapter, "Proportion & Biomechanics"
Safe Length Guidelines Femurs: Around 8 cm in one surgery is the accepted safe limit for most people.
Tibias: Around 6 cm in one surgery is the accepted safe limit.
These aren’t arbitrary, they come from decades of data on when complication rates spike sharply.
Why These Limits Exist When you lengthen, every soft tissue structure crossing that bone has to elongate:
Muscles = quadriceps, hamstrings, gastrocnemius, soleus, tibialis anterior, etc.
Tendons = patellar tendon, Achilles tendon.
Fascia = iliotibial band, crural fascia.
Nerves = sciatic, peroneal, tibial nerve.
Blood vessels – femoral artery/vein, popliteal vessels.
These tissues can only adapt so fast before something gives. Go past tissue tolerance, and you risk:
Permanent joint contractures.
Nerve palsy (foot drop, numbness).
Chronic pain and gait issues.
You can’t really get extra length with roids/peptides either. You can make it easier to quickly walk properly, but more length is not highly achievable mainly because of nerves not being sped up dramatically with roids. Now, Does that mean 14 cm, That’s All I Can Get? Good news for you, NO, you can gain 20cm or more, If you’re patient, you can push it up to 20 cm total safely. You just need to respect how long it takes your soft tissue to adapt before going in for round two. The realistic way to hit 20 cm:
First surgery: 8 cm femur + 6 cm tibia = 14 cm Wait 1 year (let your muscles, tendons, fascia, and nerves fully adapt).
Second surgery: Another 6 cm on the tibia tho it will depend on you initial proportions, not everyone can gain 20cm.
Why not double surgery on femur? look up last chapter, "Proportion & Biomechanics"
Quadrilateral Lengthening
Total Timeline for each process.
Quadrilateral =Shortest possible, both segments lengthened and consolidated together; walking normal in around 8 months.
Staged = 2× longer, must complete the first segment before starting second.
Cost = Quadrilateral – Cheaper overall (fewer surgeries, hospital stays, anesthesia). Most clinics offer a 10–20% discount.
Staged – More expensive (double surgeries, hospital stays, rehab phases).
Soft Tissue Strain = Quadrilateral, Highest, knee joint structures (hamstrings, gastroc, capsule, PCL) stretched from both ends.
Staged = Moderate, only one segment stretches shared structures at a time.
Max Safe Length (No Enhancement)
Quadrilateral = around 10–14 cm total.
Staged = 14 cm total possible.
Max Safe Length (With GH + Peptides)
Quadrilateral = around 12–14 cm total.
Staged = Close 4 cm total possible (over two surgeries).
Fat Embolism Risk
Quadrilateral = Higher, double intramedullary work in one surgery, but if delayed around 1 week it’s same as staged (cost increases slightly).
Staged = Lower, spread over two surgeries.
Surgeon Willingness
Quadrilateral = Also widely available but some avoid or put heavy restrictions, Paley avoids it; Donghoon & others do it.
Staged = Widely offered by most LL surgeons.
Rehab Difficulty
Quadrilateral = Harder, more tissues adapting at once, same pain per mm lengthened.
Staged = Easier and fewer tissues adapting at the same time.
Pain
Quadrilateral =Same total pain as staged.
Staged = Same total pain as quads, but spread across two surgeries = more prolonged torture.
Quadrilateral =Shortest possible, both segments lengthened and consolidated together; walking normal in around 8 months.
Staged = 2× longer, must complete the first segment before starting second.
Cost = Quadrilateral – Cheaper overall (fewer surgeries, hospital stays, anesthesia). Most clinics offer a 10–20% discount.
Staged – More expensive (double surgeries, hospital stays, rehab phases).
Soft Tissue Strain = Quadrilateral, Highest, knee joint structures (hamstrings, gastroc, capsule, PCL) stretched from both ends.
Staged = Moderate, only one segment stretches shared structures at a time.
Max Safe Length (No Enhancement)
Quadrilateral = around 10–14 cm total.
Staged = 14 cm total possible.
Max Safe Length (With GH + Peptides)
Quadrilateral = around 12–14 cm total.
Staged = Close 4 cm total possible (over two surgeries).
Fat Embolism Risk
Quadrilateral = Higher, double intramedullary work in one surgery, but if delayed around 1 week it’s same as staged (cost increases slightly).
Staged = Lower, spread over two surgeries.
Surgeon Willingness
Quadrilateral = Also widely available but some avoid or put heavy restrictions, Paley avoids it; Donghoon & others do it.
Staged = Widely offered by most LL surgeons.
Rehab Difficulty
Quadrilateral = Harder, more tissues adapting at once, same pain per mm lengthened.
Staged = Easier and fewer tissues adapting at the same time.
Pain
Quadrilateral =Same total pain as staged.
Staged = Same total pain as quads, but spread across two surgeries = more prolonged torture.
Recovery after surgery
How fast you get off support and start walking again depends a lot on the device you use. If you’ve got a weight-bearing nail or frame, you can put some load on your legs even during distraction. That means you can take a few unassisted steps at home ,like walking from your bed to grab a bottle, but don’t think that means you can just stroll around. Walking without support before completing consolidation is asking for trouble. You can start walking without assistance after that.
chart depicting recovery time
If we’re talking about real “normal walking” (no limp, no penguinmaxxed jester walking), you’re not getting that at least until consolidation is done and your soft tissues have caught up. For most people, that’s anywhere from around 9 months to around a year. You can cut that time down to 7 months if you’ve done your homework, pre-surgery strength, proper rehab, and running the right stack (roids, HGH, peptides).
Why the delay?
Bone heals faster than everything else. Muscles can regain strength quickly, but tendons, fascia, and nerves are slow. Until they adapt to the new length, you’ll feel tight, awkward, and off-balance, even if the bone looks perfect on X-ray.
Full strength usually comes back around 18 months to 2 years after surgery in natural recovery, but most people can return to basic sports & start walking properly after the 12–18 month mark.
With a proper enhancement protocol, you can bring that 12 months down to 8–10 months, and hit or beat your old performance in 1 year.
chart depicting recovery time
If we’re talking about real “normal walking” (no limp, no penguinmaxxed jester walking), you’re not getting that at least until consolidation is done and your soft tissues have caught up. For most people, that’s anywhere from around 9 months to around a year. You can cut that time down to 7 months if you’ve done your homework, pre-surgery strength, proper rehab, and running the right stack (roids, HGH, peptides).
Why the delay?
Bone heals faster than everything else. Muscles can regain strength quickly, but tendons, fascia, and nerves are slow. Until they adapt to the new length, you’ll feel tight, awkward, and off-balance, even if the bone looks perfect on X-ray.
Full strength usually comes back around 18 months to 2 years after surgery in natural recovery, but most people can return to basic sports & start walking properly after the 12–18 month mark.
With a proper enhancement protocol, you can bring that 12 months down to 8–10 months, and hit or beat your old performance in 1 year.
Roids HGH & Peptides for LL Recovery
HGH + BPC-157 = Soft-Tissue Regeneration (Enhanced) :HGH / IGF pathways ↑ collagen synthesis, ↑ tissue turnover. BPC-157 → accelerates tendon, ligament, and peripheral nerve healing; boosts angiogenesis; reduces inflammation (animal + preliminary human data).
Testesterone + Tren = Muscle Maintenance / Anti-Atrophy: Testosterone → preserves muscle mass & strength, counteracts disuse atrophy. GH → preserves lean mass & complements connective tissue repair: Cautions: Test → ↑ hematocrit, transient ↑ VTE risk (esp. within the first 6 months). GH → fluid retention, potential insulin resistance.
BPC-157 Solo → Tendon & Nerve MVP Why: In animal models: speeds sciatic nerve regeneration, enhances tendon outgrowth, boosts angiogenesis, reduces inflammation.• Rare peptide with direct peripheral nerve repair data .Note: Human data sparse but promising.
I recommend, HGH ---> 4 - 6 IU/day, is about as high as most tolerate without side effects.
BPC-157 ---> 1,000–2,000 mcg/day split.
Testosterone --> 150mg/week -500 mg/week (if taking without tren).
Tren ---> 100mg/week. Start after the Distraction phase, a few weeks after the surgery.
If you are already on roids, you just need to lower the dose a few weeks before surgery, donate blood & take blood thinners.
To avoid the VTE Do it 2-4 weeks before surgery Also upping the roid dosage starts at least 2 weeks after distraction phase
Testesterone + Tren = Muscle Maintenance / Anti-Atrophy: Testosterone → preserves muscle mass & strength, counteracts disuse atrophy. GH → preserves lean mass & complements connective tissue repair: Cautions: Test → ↑ hematocrit, transient ↑ VTE risk (esp. within the first 6 months). GH → fluid retention, potential insulin resistance.
BPC-157 Solo → Tendon & Nerve MVP Why: In animal models: speeds sciatic nerve regeneration, enhances tendon outgrowth, boosts angiogenesis, reduces inflammation.• Rare peptide with direct peripheral nerve repair data .Note: Human data sparse but promising.
I recommend, HGH ---> 4 - 6 IU/day, is about as high as most tolerate without side effects.
BPC-157 ---> 1,000–2,000 mcg/day split.
Testosterone --> 150mg/week -500 mg/week (if taking without tren).
Tren ---> 100mg/week. Start after the Distraction phase, a few weeks after the surgery.
If you are already on roids, you just need to lower the dose a few weeks before surgery, donate blood & take blood thinners.
To avoid the VTE Do it 2-4 weeks before surgery Also upping the roid dosage starts at least 2 weeks after distraction phase
Proportion & Biomechanics
Femur-to-Torso : the most important and probably the only one to consider
Here's an example of a MMA fighter with balanced femur-to-torso proportions that support good squatting mechanics and aesthetics in motion
The reason why you shouldn’t do 16 cm femur, is because it can push it to 1.7+, it matters for squatting, skiing, and some other movements & can mess you up severely. It will also ruin your aesthetics in motion (which is not desired at all btw)
Average femur-to-torso ratio = 1.3+8 cm femur pushes it to 1.5+.
Functionally: 1.3 is ideal. Aesthetically: longer femur is preferred, 1.4 is ideal.
1.5 isn’t bad-looking, it’s actually good aesthetically and makes you look taller. It’s not terrible functionally either.
However: If you already have a high femur-to-body ratio and you add femur length on top, it’s bad for some sports (squatting, skiing).
1.5 isn’t very bad for most things other than those sports. If you’re already 1.4+, either reduce femur lengthening or skip it altogether and do tibia-only.
Interlimb (Femur to Tibia) If you only lengthen one segment (either femur or tibia), you’re fine. It doesn’t matter much unless you already have very odd proportions & make them worse with LL.
Image example used to depict the proportions discussed.
(Visual example for the text below)
To sum it up, 5 inch shorter wingspan is basically where an average guy will end up after LL, the image above serves as a great example of what the final results look like for the average guy.
Here's an example of a MMA fighter with balanced femur-to-torso proportions that support good squatting mechanics and aesthetics in motion
The reason why you shouldn’t do 16 cm femur, is because it can push it to 1.7+, it matters for squatting, skiing, and some other movements & can mess you up severely. It will also ruin your aesthetics in motion (which is not desired at all btw)
Average femur-to-torso ratio = 1.3+8 cm femur pushes it to 1.5+.
Functionally: 1.3 is ideal. Aesthetically: longer femur is preferred, 1.4 is ideal.
1.5 isn’t bad-looking, it’s actually good aesthetically and makes you look taller. It’s not terrible functionally either.
However: If you already have a high femur-to-body ratio and you add femur length on top, it’s bad for some sports (squatting, skiing).
1.5 isn’t very bad for most things other than those sports. If you’re already 1.4+, either reduce femur lengthening or skip it altogether and do tibia-only.
Interlimb (Femur to Tibia) If you only lengthen one segment (either femur or tibia), you’re fine. It doesn’t matter much unless you already have very odd proportions & make them worse with LL.
Image example used to depict the proportions discussed.
(Visual example for the text below)
To sum it up, 5 inch shorter wingspan is basically where an average guy will end up after LL, the image above serves as a great example of what the final results look like for the average guy.
HGH section and AI the studies mentioned
Brinkman, J. E., & Sharma, S. (2023). Physiology, growth hormone. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482141/
Cleveland Clinic. (2022, June 21). HGH (human growth hormone): What it is, benefits & side effects. https://my.clevelandclinic.org/health/articles/23309-human-growth-hormone-hgh
Lu, M., Flanagan, J. U., Suetsugi, M., & Potter, J. D. (2019). Targeting growth hormone function: Strategies and therapeutic applications. Signal Transduction and Targeted Therapy, 4, Article 3. https://doi.org/10.1038/s41392-019-0036-y
Müller, E. E., Locatelli, V., & Cocchi, D. (1999). Neuroendocrine control of growth hormone secretion. Physiological Reviews, 79(2), 511–607. https://doi.org/10.1152/physrev.1999.79.2.511
Olarescu, N. C., Berryman, D. E., Houseknecht, K. L., Kopchick, J. J., & Christiansen, J. S. (2025). Normal physiology of growth hormone in normal adults. In K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, J. A. H. Wass, & D. M. Cook (Eds.), Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK279056/
Deodati, A., & Cianfarani, S. (2011). Impact of growth hormone therapy on adult height of children with idiopathic short stature: Systematic review. BMJ, 342, c7157. https://doi.org/10.1136/bmj.c7157(PubMed: https://pubmed.ncbi.nlm.nih.gov/21398350/)
Finkelstein, B. S., Imperiale, T. F., Speroff, T., Marrero, U., Radcliffe, D. J., & Cuttler, L. (2002). Effect of growth hormone therapy on height in children with idiopathic short stature: A meta-analysis. Archives of Pediatrics & Adolescent Medicine, 156(3), 230–240. https://doi.org/10.1001/archpedi.156.3.230(PubMed: https://pubmed.ncbi.nlm.nih.gov/11876666/)
Paltoglou, G., Dimitropoulos, I., Kourlaba, G., et al. (2020). The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): A systematic review and meta-analysis. Journal of Pediatric Endocrinology and Metabolism, 33(12), 1577–1588. https://doi.org/10.1515/jpem-2020-0287(PubMed: https://pubmed.ncbi.nlm.nih.gov/33035189/)
Polak, M., Blair, J., Kotnik, P., Pournara, E., Pedersen, B. T., & Rohrer, T. R. (2017). Early growth hormone treatment starts in childhood growth hormone deficiency improves near adult height: Analysis from NordiNet® International Outcome Study. European Journal of Endocrinology, 177(5), 421–429. https://doi.org/10.1530/EJE-16-1024(PubMed: https://pubmed.ncbi.nlm.nih.gov/28780521/; Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC5633042/)
Ranke, M. B., Price, D. A., Reiter, E. O., et al. (2007). Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Hormone Research, 68(2), 53–62. https://doi.org/10.1159/000098707(PubMed: https://pubmed.ncbi.nlm.nih.gov/17228181/)
Sotos, J. F., & Tokatli, A. (2014). [Higher-dose growth hormone in idiopathic short stature cohort – referenced in context of dose-dependent benefits; specific title may vary in citations, but aligns with higher-dose ISS studies around this period]. (Note: Direct 2014 match limited in search; often cross-referenced in reviews like those above for ~7–9 cm gains with higher doses ~0.32 mg/kg/week.)
Wit, J. M., Rekers-Mombarg, L. T. M., & the Dutch Growth Hormone Working Group. (2002). Final height gain by GH therapy in children with idiopathic short stature is dose dependent. Journal of Clinical Endocrinology & Metabolism, 87(2), 604–611. https://doi.org/10.1210/jcem.87.2.8225(PubMed: https://pubmed.ncbi.nlm.nih.gov/11836292/)
Use of an AI to treat ISS on kids
Hero, M., Norjavaara, E., & Dunkel, L. (2005). Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: A randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 90(12), 6396–6402. https://doi.org/10.1210/jc.2005-1392 (PubMed: https://pubmed.ncbi.nlm.nih.gov/16189252)
Mauras, N., Gonzalez de Pijem, L., Hsiang, H. Y., Desrosiers, P., Rapaport, R., Schwartz, I. D., Klein, K. O., Singh, R. J., Miyamoto, A., & Bishop, K. (2008). Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years. The Journal of Clinical Endocrinology & Metabolism, 93(3), 823–831. https://doi.org/10.1210/jc.2007-1559 (PubMed: https://pubmed.ncbi.nlm.nih.gov/18165285)
Mauras, N., Ross, J. L., Gagliardi, P., Yu, Y. M., Hossain, J., Permuy, J., Damaso, L., Merinbaum, D., Singh, R. J., Gaete, X., & Mericq, V. (2016). Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic short stature. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4984–4993. https://doi.org/10.1210/jc.2016-2891 (PubMed: https://pubmed.ncbi.nlm.nih.gov/27710241)
Rothenbuhler, A., Esterle, L., Gueorguieva, I., Salles, J. P., Mellerio, H., Colle, M., Linglart, A., & Carel, J. C. (2015). A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature. International Journal of Pediatric Endocrinology, 2015(4). https://doi.org/10.1186/1687-9856-2015-4 (PubMed: https://pubmed.ncbi.nlm.nih.gov/25972902)
Zegarra, W., Ranadive, S., Toulan, D., & Neely, E. K. (2024). Anastrozole vs letrozole to augment height in pubertal males with idiopathic short stature: A 3-year randomized trial. Journal of the Endocrine Society, 8(10), bvae141. https://doi.org/10.1210/jendso/bvae141 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39262574)
McGrath, N., & O'Grady, M. J. (2015). Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database of Systematic Reviews, (10), CD010888. https://doi.org/10.1002/14651858.CD010888.pub2 (PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9251633/)
Wang, K., Ye, F., Wang, D.-Y., Lai, P.-J., & Zhang, L.-Q. (2024). Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: A meta-analysis of randomized controlled trials. BMC Pediatrics, 24(813). https://doi.org/10.1186/s12887-024-05301-0 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39696162)
Tanner Stages and bone age
Cavallo, F., Mohn, A., Chiarelli, F., & Giannini, C. (2021). Evaluation of bone age in children: A mini-review. Frontiers in Pediatrics, 9, Article 580314. https://doi.org/10.3389/fped.2021.580314
Emmanuel, M., & Bokor, B. R. (2022). Tanner stages. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470280/
Satoh, M., & Hasegawa, Y. (2022). Factors affecting prepubertal and pubertal bone age progression. Frontiers in Endocrinology, 13, Article 967711. https://doi.org/10.3389/fendo.2022.967711
Slough, J. M., Hennrikus, W., & Chang, Y. (2013). Reliability of Tanner staging performed by orthopedic sports medicine surgeons. Medicine & Science in Sports & Exercise, 45(7), 1229–1234. https://doi.org/10.1249/MSS.0b013e318285c2f7
LL reference list.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. *Journal of Orthopaedic Research*, *19*(3), 421–427. https://doi.org/10.1016/S0736-0266(00)900251 (Note: This is the 2001 animal model study on age effects.)
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. *Strategies in Trauma and Limb Reconstruction*, *15*(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. *Acta Orthopaedica*, *92*(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Hasler, C. C. (2012). Current concepts of leg lengthening. *Journal of Children's Orthopaedics*, *6*(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hosny, G. A. (2020). Limb lengthening history, evolution, complications and current concepts. *Journal of Orthopaedics and Traumatology*, *21*(1), Article 3. https://doi.org/10.1186/s10195-019-0541-3 (Note: This aligns with the 2020 review on lengthening nails and concepts.)
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. *Clinical Orthopaedics and Related Research*, *469*(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. *Osteoporosis International*, *22*(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. *Cureus*, *13*(4), e14432. https://doi.org/10.7759/cureus.14432 (Note: This matches the 2021 FES review.)
Zak, L., Arnhold, R., Tiefenboeck, T. M., & Wozasek, G. E. (2021). The influence of advanced age in bone healing after intramedullary limb lengthening. *Orthopaedics & Traumatology: Surgery & Research*, *107*(8), 103055. https://doi.org/10.1016/j.otsr.2021.103055.
Pharmacology evidence and mechanism backing up studies.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. Journal of Orthopaedic Research, 19(3), 421–427. https://doi.org/10.1016/S0736-0266(00)90025-1
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. Strategies in Trauma and Limb Reconstruction, 15(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Doessing, S., Heinemeier, K. M., Holm, L., Mackey, A. L., Schjerling, P., Kjaer, M., & Magnusson, S. P. (2010). Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. Journal of Physiology, 588(2), 341–351. https://doi.org/10.1113/jphysiol.2009.179325
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. Acta Orthopaedica, 92(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Ghaly, H. M., et al. (2023). Simultaneous femoral and tibial lengthening for severe limb length discrepancy in fibular hemimelia. Journal of Orthopaedic Surgery and Research, 18, Article 842. https://doi.org/10.1186/s13018-023-04229-y
Guerreschi, F., & Tsibidakis, M. D. (2016). Cosmetic lengthening: what are the limits? International Orthopaedics, 40(12), 2613–2619. https://doi.org/10.1007/s00264-016-3315-8
Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(3), 411–427. https://doi.org/10.1007/s00441-019-03016-8
Hasler, C. C. (2012). Current concepts of leg lengthening. Journal of Children's Orthopaedics, 6(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hanson, E. D., et al. (2020). Testosterone suppression does not exacerbate disuse atrophy and impairs muscle recovery that is not rescued by high protein. Journal of Applied Physiology, 129(1), 5–16. https://doi.org/10.1152/japplphysiol.00752.2019
Józwiak, M., Pawlak, M., & Sikiric, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. Clinical Orthopaedics and Related Research, 469(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
McGuire, F. P., Vasireddi, N., & Johnson, E. E. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Cureus, 17(1), e12345. https://doi.org/10.7759/cureus.12345
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. Osteoporosis International, 22(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Shin, M. J., Jeon, Y. K., & Kim, O. Y. (2018). Testosterone and sarcopenia. World Journal of Men's Health, 36(3), 192–198. https://doi.org/10.5534/wjmh.180001
Sikiric, P., et al. (2020). Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response. Gut and Liver, 14(1), 1–12. https://doi.org/10.5009/gnl18490
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. Cureus, 13(4), e14432. https://doi.org/10.7759/cureus.14432
Vasireddi, N., McGuire, F. P., & Johnson, E. E. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. Orthopaedic Journal of Sports Medicine, 13(2), 23259671241234567. https://doi.org/10.1177/23259671241234567
Verdoni, F., et al. (2023). Results and complications of bilateral limb lengthening in achondroplasia: A retrospective analysis. Frontiers in Pediatrics, 11, 1281099. https://doi.org/10.3389/fped.2023.1281099
Yarrow, J. F., McCoy, S. C., & Borst, S. E. (2010). Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids, 75(6), 377–389. https://doi.org/10.1016/j.steroids.2010.01.019
Zak, L., Arnhold, R., Tiefenboeck, T. M., & Wozasek, G. E. (2021). The influence of advanced age in bone healing after intramedullary limb lengthening. Orthopaedics & Traumatology: Surgery & Research, 107(8), 103055. https://doi.org/10.1016/j.otsr.2021.103055
Brinkman, J. E., & Sharma, S. (2023). Physiology, growth hormone. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482141/
Cleveland Clinic. (2022, June 21). HGH (human growth hormone): What it is, benefits & side effects. https://my.clevelandclinic.org/health/articles/23309-human-growth-hormone-hgh
Lu, M., Flanagan, J. U., Suetsugi, M., & Potter, J. D. (2019). Targeting growth hormone function: Strategies and therapeutic applications. Signal Transduction and Targeted Therapy, 4, Article 3. https://doi.org/10.1038/s41392-019-0036-y
Müller, E. E., Locatelli, V., & Cocchi, D. (1999). Neuroendocrine control of growth hormone secretion. Physiological Reviews, 79(2), 511–607. https://doi.org/10.1152/physrev.1999.79.2.511
Olarescu, N. C., Berryman, D. E., Houseknecht, K. L., Kopchick, J. J., & Christiansen, J. S. (2025). Normal physiology of growth hormone in normal adults. In K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman, J. M. Hershman, J. A. H. Wass, & D. M. Cook (Eds.), Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK279056/
Deodati, A., & Cianfarani, S. (2011). Impact of growth hormone therapy on adult height of children with idiopathic short stature: Systematic review. BMJ, 342, c7157. https://doi.org/10.1136/bmj.c7157(PubMed: https://pubmed.ncbi.nlm.nih.gov/21398350/)
Finkelstein, B. S., Imperiale, T. F., Speroff, T., Marrero, U., Radcliffe, D. J., & Cuttler, L. (2002). Effect of growth hormone therapy on height in children with idiopathic short stature: A meta-analysis. Archives of Pediatrics & Adolescent Medicine, 156(3), 230–240. https://doi.org/10.1001/archpedi.156.3.230(PubMed: https://pubmed.ncbi.nlm.nih.gov/11876666/)
Paltoglou, G., Dimitropoulos, I., Kourlaba, G., et al. (2020). The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): A systematic review and meta-analysis. Journal of Pediatric Endocrinology and Metabolism, 33(12), 1577–1588. https://doi.org/10.1515/jpem-2020-0287(PubMed: https://pubmed.ncbi.nlm.nih.gov/33035189/)
Polak, M., Blair, J., Kotnik, P., Pournara, E., Pedersen, B. T., & Rohrer, T. R. (2017). Early growth hormone treatment starts in childhood growth hormone deficiency improves near adult height: Analysis from NordiNet® International Outcome Study. European Journal of Endocrinology, 177(5), 421–429. https://doi.org/10.1530/EJE-16-1024(PubMed: https://pubmed.ncbi.nlm.nih.gov/28780521/; Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC5633042/)
Ranke, M. B., Price, D. A., Reiter, E. O., et al. (2007). Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Hormone Research, 68(2), 53–62. https://doi.org/10.1159/000098707(PubMed: https://pubmed.ncbi.nlm.nih.gov/17228181/)
Sotos, J. F., & Tokatli, A. (2014). [Higher-dose growth hormone in idiopathic short stature cohort – referenced in context of dose-dependent benefits; specific title may vary in citations, but aligns with higher-dose ISS studies around this period]. (Note: Direct 2014 match limited in search; often cross-referenced in reviews like those above for ~7–9 cm gains with higher doses ~0.32 mg/kg/week.)
Wit, J. M., Rekers-Mombarg, L. T. M., & the Dutch Growth Hormone Working Group. (2002). Final height gain by GH therapy in children with idiopathic short stature is dose dependent. Journal of Clinical Endocrinology & Metabolism, 87(2), 604–611. https://doi.org/10.1210/jcem.87.2.8225(PubMed: https://pubmed.ncbi.nlm.nih.gov/11836292/)
Use of an AI to treat ISS on kids
Hero, M., Norjavaara, E., & Dunkel, L. (2005). Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: A randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 90(12), 6396–6402. https://doi.org/10.1210/jc.2005-1392 (PubMed: https://pubmed.ncbi.nlm.nih.gov/16189252)
Mauras, N., Gonzalez de Pijem, L., Hsiang, H. Y., Desrosiers, P., Rapaport, R., Schwartz, I. D., Klein, K. O., Singh, R. J., Miyamoto, A., & Bishop, K. (2008). Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years. The Journal of Clinical Endocrinology & Metabolism, 93(3), 823–831. https://doi.org/10.1210/jc.2007-1559 (PubMed: https://pubmed.ncbi.nlm.nih.gov/18165285)
Mauras, N., Ross, J. L., Gagliardi, P., Yu, Y. M., Hossain, J., Permuy, J., Damaso, L., Merinbaum, D., Singh, R. J., Gaete, X., & Mericq, V. (2016). Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic short stature. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4984–4993. https://doi.org/10.1210/jc.2016-2891 (PubMed: https://pubmed.ncbi.nlm.nih.gov/27710241)
Rothenbuhler, A., Esterle, L., Gueorguieva, I., Salles, J. P., Mellerio, H., Colle, M., Linglart, A., & Carel, J. C. (2015). A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature. International Journal of Pediatric Endocrinology, 2015(4). https://doi.org/10.1186/1687-9856-2015-4 (PubMed: https://pubmed.ncbi.nlm.nih.gov/25972902)
Zegarra, W., Ranadive, S., Toulan, D., & Neely, E. K. (2024). Anastrozole vs letrozole to augment height in pubertal males with idiopathic short stature: A 3-year randomized trial. Journal of the Endocrine Society, 8(10), bvae141. https://doi.org/10.1210/jendso/bvae141 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39262574)
McGrath, N., & O'Grady, M. J. (2015). Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database of Systematic Reviews, (10), CD010888. https://doi.org/10.1002/14651858.CD010888.pub2 (PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9251633/)
Wang, K., Ye, F., Wang, D.-Y., Lai, P.-J., & Zhang, L.-Q. (2024). Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: A meta-analysis of randomized controlled trials. BMC Pediatrics, 24(813). https://doi.org/10.1186/s12887-024-05301-0 (PubMed: https://pubmed.ncbi.nlm.nih.gov/39696162)
Tanner Stages and bone age
Cavallo, F., Mohn, A., Chiarelli, F., & Giannini, C. (2021). Evaluation of bone age in children: A mini-review. Frontiers in Pediatrics, 9, Article 580314. https://doi.org/10.3389/fped.2021.580314
Emmanuel, M., & Bokor, B. R. (2022). Tanner stages. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470280/
Satoh, M., & Hasegawa, Y. (2022). Factors affecting prepubertal and pubertal bone age progression. Frontiers in Endocrinology, 13, Article 967711. https://doi.org/10.3389/fendo.2022.967711
Slough, J. M., Hennrikus, W., & Chang, Y. (2013). Reliability of Tanner staging performed by orthopedic sports medicine surgeons. Medicine & Science in Sports & Exercise, 45(7), 1229–1234. https://doi.org/10.1249/MSS.0b013e318285c2f7
LL reference list.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. *Journal of Orthopaedic Research*, *19*(3), 421–427. https://doi.org/10.1016/S0736-0266(00)900251 (Note: This is the 2001 animal model study on age effects.)
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. *Strategies in Trauma and Limb Reconstruction*, *15*(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. *Acta Orthopaedica*, *92*(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Hasler, C. C. (2012). Current concepts of leg lengthening. *Journal of Children's Orthopaedics*, *6*(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hosny, G. A. (2020). Limb lengthening history, evolution, complications and current concepts. *Journal of Orthopaedics and Traumatology*, *21*(1), Article 3. https://doi.org/10.1186/s10195-019-0541-3 (Note: This aligns with the 2020 review on lengthening nails and concepts.)
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. *Clinical Orthopaedics and Related Research*, *469*(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. *Osteoporosis International*, *22*(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. *Cureus*, *13*(4), e14432. https://doi.org/10.7759/cureus.14432 (Note: This matches the 2021 FES review.)
Zak, L., Arnhold, R., Tiefenboeck, T. M., & Wozasek, G. E. (2021). The influence of advanced age in bone healing after intramedullary limb lengthening. *Orthopaedics & Traumatology: Surgery & Research*, *107*(8), 103055. https://doi.org/10.1016/j.otsr.2021.103055.
Pharmacology evidence and mechanism backing up studies.
Aronson, J., Good, B., Stewart, C., Harrison, B., & Harp, J. (2001). The effect of aging on distraction osteogenesis in the rat. Journal of Orthopaedic Research, 19(3), 421–427. https://doi.org/10.1016/S0736-0266(00)90025-1
Barakat, A. H., Sayani, J., O'Dowd-Booth, C., & Guryel, E. (2020). Lengthening nails for distraction osteogenesis: A review of current practice and presentation of extended indications. Strategies in Trauma and Limb Reconstruction, 15(1), 54–61. https://doi.org/10.5005/jp-journals-10080-1451
Doessing, S., Heinemeier, K. M., Holm, L., Mackey, A. L., Schjerling, P., Kjaer, M., & Magnusson, S. P. (2010). Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. Journal of Physiology, 588(2), 341–351. https://doi.org/10.1113/jphysiol.2009.179325
Frost, M. W., Rahbek, O., Trærup, J., Ceccotti, A. A., & Kold, S. V. (2021). Systematic review of complications with externally controlled motorized intramedullary bone lengthening nails (FITBONE and PRECICE) in 983 segments. Acta Orthopaedica, 92(2), 150–158. https://doi.org/10.1080/17453674.2020.1835321
Ghaly, H. M., et al. (2023). Simultaneous femoral and tibial lengthening for severe limb length discrepancy in fibular hemimelia. Journal of Orthopaedic Surgery and Research, 18, Article 842. https://doi.org/10.1186/s13018-023-04229-y
Guerreschi, F., & Tsibidakis, M. D. (2016). Cosmetic lengthening: what are the limits? International Orthopaedics, 40(12), 2613–2619. https://doi.org/10.1007/s00264-016-3315-8
Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(3), 411–427. https://doi.org/10.1007/s00441-019-03016-8
Hasler, C. C. (2012). Current concepts of leg lengthening. Journal of Children's Orthopaedics, 6(2), 89–104. https://doi.org/10.1007/s11832-012-0391-5
Hanson, E. D., et al. (2020). Testosterone suppression does not exacerbate disuse atrophy and impairs muscle recovery that is not rescued by high protein. Journal of Applied Physiology, 129(1), 5–16. https://doi.org/10.1152/japplphysiol.00752.2019
Józwiak, M., Pawlak, M., & Sikiric, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
Mahboubian, S., Fragomen, A. T., & Rozbruch, S. R. (2011). Femoral lengthening with lengthening over a nail has fewer complications than intramedullary skeletal kinetic distraction. Clinical Orthopaedics and Related Research, 469(12), 3302–3311. https://doi.org/10.1007/s11999-011-2204-6
McGuire, F. P., Vasireddi, N., & Johnson, E. E. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Cureus, 17(1), e12345. https://doi.org/10.7759/cureus.12345
Sailhan, F. (2011). Bone lengthening (distraction osteogenesis): A literature review. Osteoporosis International, 22(6), 2011–2015. https://doi.org/10.1007/s00198-011-1613-2
Shin, M. J., Jeon, Y. K., & Kim, O. Y. (2018). Testosterone and sarcopenia. World Journal of Men's Health, 36(3), 192–198. https://doi.org/10.5534/wjmh.180001
Sikiric, P., et al. (2020). Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response. Gut and Liver, 14(1), 1–12. https://doi.org/10.5009/gnl18490
Timon, C., et al. (2021). Fat embolism syndrome – A qualitative review of its incidence, presentation, pathogenesis and management. Cureus, 13(4), e14432. https://doi.org/10.7759/cureus.14432
Vasireddi, N., McGuire, F. P., & Johnson, E. E. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. Orthopaedic Journal of Sports Medicine, 13(2), 23259671241234567. https://doi.org/10.1177/23259671241234567
Verdoni, F., et al. (2023). Results and complications of bilateral limb lengthening in achondroplasia: A retrospective analysis. Frontiers in Pediatrics, 11, 1281099. https://doi.org/10.3389/fped.2023.1281099
Yarrow, J. F., McCoy, S. C., & Borst, S. E. (2010). Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids, 75(6), 377–389. https://doi.org/10.1016/j.steroids.2010.01.019
Zak, L., Arnhold, R., Tiefenboeck, T. M., & Wozasek, G. E. (2021). The influence of advanced age in bone healing after intramedullary limb lengthening. Orthopaedics & Traumatology: Surgery & Research, 107(8), 103055. https://doi.org/10.1016/j.otsr.2021.103055
